HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Kardan, A. Articles by Fischman, A. PubMed Articles by Kardan, A. Articles by Fischman, A.

A phase I study evaluating myocardial pharmacokinetic behavior of CardioPET, a new cardiac PET tracer, in normal subjects and subjects with stable coronary artery disease

¹ Nuclear Medicine, Massachusetts General Hospital, Boston, Massachusetts

834

Objectives: CardioPET (trans-9-[¹⁸F]fluoro-3,4-methyleneheptadecanoic acid), a modified fatty acid closely resembling naturally occurring fatty acids, undergoes metabolic trapping in heart tissue. This objective of this study was to evaluate the myocardial pharmacokinetic behavior of CardioPET.

Methods: Six normal volunteers and 4 stable CAD subjects, between 50-85 years of age, were included in a 3 day study protocol: day 1, potential subjects were screened and eligible subjects enrolled; day 2, subjects recieved CardioPET injection with PET imaging; day 3, follow-up. Primary safety endpoints included: vital signs, physical examinations, 12-Lead Electrocardiograms (ECGs), 24-Hour Holter Monitoring, and clinical laboratory tests (blood and urine). Imaging entailed a positioning and attenuation scan, followed by injection of approximately 10 mCi (370 mBq) of CardioPET and serial imaging of the heart over 60 minutes followed by a gated acquisition phase.

Results: Excllent quality cardiac images were obtained in all patients. Heart uptake was rapid and pronounced. Liver-to-heart ratios varied from 4:1 to less than 2:1. Heart activity remained constant over the 60 minute imaging period, while liver activity declined. Images of CAD subjects demonstrated reduction of tracer accumulation in sites previously reported as infarct on Myocardial Perfusion Imaging with SPECT. Gated acquisition images revealed appropriate left ventricular thickening.

Conclusions: CardioPET injected in normal healthy voluteers and CAD subjects is safe. Cardiac pharmacokinetics allow for high-resolution myocardial imaging.

This Article Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Kardan, A. Articles by Fischman, A. PubMed Articles by Kardan, A. Articles by Fischman, A.